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Local order: According to NCBI Map Viewer, SEP15 
gene is located between: SH3GLB1 (SH3-domain 
GRB2-like endophilin B1), RPL17P5 (ribosomal 
protein L17 pseudogene 5) (in telomeric position), 
HS2ST1 (heparan sulfate 2-O-sulfotransferase 1) and 
potential gene LOC339524 (in centromeric position). 
Note: SEP15 is one of the 25 genes encoding human 
selenoproteins. The product of this gene, 15 kDa 
selenoprotein contains selenocysteine (Sec), which is 
encoded (like in the case of all selenoproteins) by the 
UGA codon, normally serving as stop/termination 
codon. Due to specific mechanism involving 
selenocysteine insertion sequence (SECIS), a secondary 
DNA structure common for all selenoproteins, UGA 






Genetic locus of SEP15, 1p31 is commonly mutated or 
deleted in human cancer. 
Description 
The genomic DNA of SEP15 spans about 52 kb. The 
gene consists of 5 exons, with the Sec codon being 
placed in exon 3 (codon 93). Specific stem loop 
structure called SECIS element is present within 3'-
untranslated region of mRNA. Second stem loop 
structure close to SECIS element was identified, but it 
is not active (does not take part in the translation 
process). Structure of 15-kDa selenoprotein cDNA 
sequence is presented in figure 1. Single nucleotid 
polymorphism (SNP) within SEP15 SECIS element 
was identified, which is associated with G/A transition 
at position 1125 (rs5859). SEP15 1125G/A 
polymorphism was shown in in vitro studies to 
influence the efficiency of Sec codon (UGA) 
readthrough during translation process. 
 
Figure 1. Structural organization of the human SEP15 cDNA sequence with the relative positions of ATG initiation and the TGA Sec 
codons, the TAA termination signal, the detected polymorphisms (C811T in the SECIS-like structure and G1125A in the SECIS element), 
alternative 3'-end sequences (position 1244 or 1519 within the cDNA) of exon 5. Short vertical lines correspond to exon-exon junctions 
and number under junction sites correspond to the last nucleotides in the preceding exons (adapted with minimal modification from 
Kumaraswamy et al., 2000). 
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Other investigated SNPs within SEP15 gene: rs5845, 
rs479341, rs56104, rs527281, rs1407131. 
Transcription 
Two alternative transcripts of SEP15 exist. Transcript 
variant 1 is longer and consists of 5 exons. Transcript 
variant 2 lacks an exon in the 3' coding region. 
Compared to isoform 1, the isoform 2 has a shorter and 
distinct C-terminus. 
Pseudogene 




15 kDa selenoprotein was described for the first time n 
1995 by Kacklosch et al., who found the protein in rat 
prostate. In 1998 the protein was identified in humans, 
by Gladyshev et al. 
SEP15 possesses enzymatic activity of oxidoreductase 
and catalyzes disulfide bonds formation. The protein 
contains one atom of selenium which is present in the 
form of selenocysteine. Selenium is involved in human 
cancer development, playing dual role in this process - 
from protection to promotion. It is supposed that role of 
selenium in cancer may be partially associated with 
selenoproteins, including SEP15. 
Description 
162 amino acids, with size of 17790 Da. Possesses 
redox activity due to Cys-X-Sec motif (similar to Cys-
X-X-Cys motif present in thioredoxin). 
Expression 
Highly expressed in prostate, liver, brain, kidneys and 
testis. The protein expression was shown to be 
increased in colon cancer and decreased in liver cancer 
and prostate cancer. 
Localisation 
Endoplasmic reticulum lumen. 
Function 
Studies in vitro suggest that SEP15 is involved in the 
process of posttranslational protein folding. It forms a 
1:1 complex with the UDP-glucose: glycoprotein 
glucosyltransferase (UGGT), an enzyme that is 
responsible for quality control in the endoplasmic 
reticulum by oxidative folding and structural 
maturation of N-glycosylated proteins. It is supposed 
that SEP15 serves as a disulfide isomerase of 
glycoproteins targeted by UGGT. Due to redox activity 
it may also function as an antioxidant. 
Homology 




selenoprotein, SelM. Intraspecies homologs of SEP15  
are highly conserved and were identified in dog, cow, 
mouse, rat, chicken, zebrafish, fruit fly, mosquito, C. 
elegans, A. thaliana and rice. 
Mutations 
Note 




Hu et al. (2001) found statistically significant 
difference in SEP15 allelic distribution for rs5859 
between breast cancer individuals (DNA obtained from 
tumours, n=60) and cancer-free individuals (DNA 
obtained from lymphocytes, n=490) among African 
Americans. 
Studies conducted by Nasr et al. (2003) also suggest 
possible role of SEP15 in breast cancer development 
among African American women. The authors used 
four highly polymorphic microsatellite markers on the 
chromosome 1 region that includes SEP15 gene, to 
assess the difference in heterozygosity index at studied 
loci between DNA obtained from breast cancer 
tumours (n=61) and DNA obtained from lymphocytes 
of cancer-free individuals (n=50). Significant reduction 
of heterozygosity was found for locus that was most 
tightly linked to SEP15 gene. 
Head and neck cancer 
Disease 
Hu et al. (2001) found statistically significant 
difference in SEP15 allelic distribution for rs5859 
between head and neck cancer individuals (DNA 
obtained from tumours, n=33) and cancer-free 
individuals (DNA obtained from lymphocytes, n=490) 
among African Americans. 
Mesothelioma 
Disease 
Apostolou et al. (2004) reported that SEP15 gene 
expression was downregulated in malignant 
mesothelioma (MM) cell lines (14 out of 23 cell lines 
examined) and mesothelioma tumours (3 out of 5 tissue 
specimens examined). The authors examined also the 
effect of selenium in MM cell lines on the growth 
inhibition and apoptosis. They observed that 
suppression of SEP15 expression by siRNA affected 
the response of cells to selenium, making them more 
resistant to the microelement. The growth inhibition 
and apoptosis effects followed by selenium treatmen 
were also less pronounced in cells with variant alleles 
of SEP15 (SEP15 1125A, rs5859) as compared to cells 
with wild type allele (SEP15 1125G). 
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Lung cancer 
Disease 
In the case control study (238 cases, 340 controls), 
Jablonska et al. (2008) observed a modifying effect of 
SEP15 polymorphism (rs5859) on lung cancer risk 
associated with selenium status. The high risk of lung 
cancer in the studied group was associated with low as 
well as with high plasma selenium concentration. After 
stratifying the data according to SEP15 genotype, it 
was found that among individuals with high selenium 
status, the risk of lung cancer was increased among 
those possessing at least one wild type allele, whereas 
in those with both variant alleles, the risk was 
decreased (figure 2). 
No expression change for SEP15 was observed 
between malignant and non-malignant lung tissue 
(study of 33 non-small cell lung cancer patients, 
conducted by Gresner et al., 2009). 
 
Figure 2. Joint effect of plasma selenium concentration and 
SEP15 1125G/A polymorphism for lung cancer development. 
OR - Odds Ratio for lung cancer risk. SEP15 genotypes: 
1125GG (black line), 1125GA (yellow line), 1125AA (red line). 
Test for trends in SEP15 genotypes: p=0.038 for GG, p=0.035 
for GA, p=0.030 for AA. Test for trend differences: AA vs. GG: 
p=0.049, AA vs. GA: p=0.025 (results of this study were 
published in Jablonska et al., 2008). 
Bladder cancer 
Disease 
Reszka et al. (2009) indicated that SEP15 was down 
expressed in the blood leucocytes of bladder cancer 
patients (33 males) as compared to healthy controls (47 
males). SEP15 expression was positively correlated 
with tumour grade. 
Prostate cancer 
Disease 
Penney et al. (2010) conducted nested case control 
study among 1286 cases and 1267 controls to assess the 
relationship between five SEP15 polymorphisms 
(rs5859, rs479341, rs561104, rs527281, rs1407131), 
selenium status and prostate cancer risk and survival. 
Authors did not found any association between SEP15 
polymorphisms and prostate cancer risk. However they
observed that three variants (rs479341, rs1407131 and 
rs561104) were significantly associated with prostate 
cancer mortality and and one of the SNPs (rs561104) 
was shown to modify prostate cancer survival in 
association with selenium status. 
Colon/colorectal cancer 
Disease 
Studies conducted in mice by Irons et al. (2010), 
showed that down regulation of SEP15 inhibited colon 
cancer development induced by injection of mouse 
CT26 colon cancer cells. Authors suggest that targeed 
down regulation of SEP15 in colon cancer cells may 
protect them from tumorigenesis. 
Meplan et al. (2010) conducted case control study 
including 832 cases and 705 controls, in which they 
assessed the association between colorectal cancer d 
several SNPs within genes encoding selenoproteins and 
also other proteins. They found significant two-loci 
interaction between SEP15 (rs5859) and other 
selenoprotein (Sepp1) associated with colon cancer 
risk. 
In a similar study, involving 827 cases and 733 
controls, Sutherland et al. (2010) found two SNPs 
within SEP15 (rs5845 and rs5859) to be associated 
with colorectal cancer risk. 
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